🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Sweden / NCT06874231
Recruiting Observational

Brain Connectivity Marker for Alzheimer's Disease

NCT06874231 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2023-04-01
Last updated
2025-03-17

Condition(s) studied

Alzheimer Disease

Investigational drug(s) / intervention(s)

Neuroimaging

Neuroimaging: The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples

Study summary

The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Inclusion criteria for subjects with subjective cognitive complaints: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30. * Absence of cognitive impairment. * Memory problems reported by the participant/family member. * Do not fulfill criteria for mild cognitive impairment or dementia. * Must speak and understand Swedish. 2. Inclusion criteria for patients with mild cognitive impairment: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30. * Impaired memory function. * Do not fulfill criteria for dementia. * Must speak and understand Swedish. * Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease. 3. Specific inclusion criteria for patients with Alzheimer's disease: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28. * Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed. * Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease. * Must speak and understand Swedish. * Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease. Exclusion Criteria: * Alcohol or drug abuse. * Unstable somatic disease or organ failure. * Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram. In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Karolinska University Hospital Stockholm Solna Recruiting

More Karolinska Institutet trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06874231 on ClinicalTrials.gov ↗ ← All trials in Sweden